Step 1 topics → Hematology and Oncology → Hemophilia A and B

Hemophilia A and B

USMLE Step 1 trap: Overapplies DDAVP to all hemophilia A without restricting it to mild disease. DDAVP is effective only in mild hemophilia A by releasing endothelial vWF and Factor VIII stores; it is ineffective in moderate-to-severe disease and has no role in hemophilia B.

Hemophilia A and B are X-linked recessive coagulation disorders caused by deficiency of Factor VIII (A) and Factor IX (B), respectively. USMLE Step 1 tests this topic heavily — and the most common management error is using DDAVP in moderate-to-severe hemophilia A or in any hemophilia B patient. DDAVP only works if there are Factor VIII stores to release, which means it helps only in mild hemophilia A. Both disorders disrupt the intrinsic pathway, producing a prolonged PTT with normal PT and normal platelet count, and questions will ask you to distinguish the two, explain the bleeding pattern, and choose correctly between DDAVP and factor concentrate.

The exam tests this at multiple levels. Pure recall questions ask you to match the factor defect to the disease name (don't forget hemophilia C is Factor XI deficiency — autosomal, not X-linked, and typically milder). Application questions present a patient with hemarthroses or muscle hematomas and a coag panel showing isolated PTT prolongation that corrects on mixing study, then ask you to identify the diagnosis, interpret severity, or choose management. Passage-based questions may embed the genetic history (maternal carrier, affected brothers) to test inheritance pattern recognition.

The trickiest parts involve DDAVP (students overapply it to all hemophilia A) and the bleeding pattern (students confuse it with platelet disorders). The mixing study is also a key discriminator on USMLE Step 1 — a correcting mix tells you factor deficiency, while a non-correcting mix points to an inhibitor, which completely changes management. Get these distinctions sharp before test day.

From real student decks
73%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: DDAVP is used for all hemophilia A patients regardless of severity.
Right: DDAVP is effective only in mild hemophilia A by releasing endothelial vWF and Factor VIII stores; it is ineffective in moderate-to-severe disease and has no role in hemophilia B.
DDAVP works by triggering release of preformed Factor VIII and vWF from endothelial Weibel-Palade bodies, so it only helps patients who have some endogenous Factor VIII stores to release — that means mild hemophilia A only. In moderate-to-severe disease, there simply isn't enough Factor VIII stored to make a meaningful difference, so DDAVP won't raise levels adequately. DDAVP also has zero role in hemophilia B because it does not affect Factor IX at all.
Common mistake
Wrong: Patients with hemophilia who develop inhibitors should receive higher doses of the deficient factor.
Right: Inhibitor-complicated hemophilia is managed with bypassing agents (recombinant Factor VIIa or activated prothrombin complex concentrate) that circumvent the inhibited factor.
About 30% of severe hemophilia A patients develop alloantibodies (inhibitors) against Factor VIII after repeated exposure to exogenous factor concentrate. Once an inhibitor is present, giving more of the same factor just gets neutralized — it doesn't work and can even accelerate antibody titers. The correct move is to bypass the inhibited step entirely using recombinant Factor VIIa or activated prothrombin complex concentrate (aPCC), which generate thrombin through alternative routes that don't require the inhibited factor.
Common mistake
Wrong: Hemophilia presents with petechiae and mucosal bleeding similar to platelet disorders.
Right: Hemophilia presents with deep tissue bleeding (hemarthroses, muscle hematomas) reflecting a coagulation factor deficiency, not the superficial mucocutaneous bleeding of platelet disorders.
The bleeding pattern reflects the mechanism of deficiency. Platelet disorders disrupt primary hemostasis — the formation of the initial platelet plug — so you get superficial mucocutaneous bleeding: petechiae, purpura, gum bleeding, epistaxis. Hemophilia disrupts secondary hemostasis — the coagulation cascade that reinforces the clot — so bleeding occurs in deep tissues that require a robust fibrin clot: joint spaces (hemarthroses), muscle, and retroperitoneum. Seeing petechiae in a vignette should immediately steer you away from hemophilia.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the inheritance pattern (X-linked recessive) and the specific factor deficient in hemophilia A (Factor VIII), hemophilia B (Factor IX, aka Christmas disease), and hemophilia C (Factor XI — autosomal recessive, not X-linked).
  2. Recognize the bleeding pattern of coagulation factor deficiency: deep tissue bleeding (hemarthroses, muscle hematomas, retroperitoneal bleeds) — not petechiae or gum bleeding, which point to platelet problems.
  3. Interpret the coagulation panel: isolated PTT prolongation with normal PT and normal platelet count; understand that a mixing study corrects with factor deficiency but fails to correct when an inhibitor is present; know how factor activity levels stratify disease into mild (>5%), moderate (1–5%), and severe (<1%).
  4. Apply the right management: mild hemophilia A → DDAVP; moderate-to-severe hemophilia A and all hemophilia B → factor concentrate replacement; inhibitor-complicating hemophilia → bypassing agents (recombinant Factor VIIa or aPCC), NOT higher doses of the deficient factor.

Can you avoid these mistakes?

A 6-year-old boy presents with recurrent knee swelling after minor trauma. Labs show PTT 68 sec, PT normal, platelets normal. Mixing study corrects the PTT. His maternal uncle had the same condition. What is the most likely diagnosis, and what single lab would you order next to distinguish hemophilia A from hemophilia B?
A patient with known severe hemophilia A is started on Factor VIII concentrate but continues to bleed despite escalating doses. His mixing study no longer corrects. What complication has developed, and what is the appropriate next step in management?
You are deciding between DDAVP and Factor VIII concentrate for a hemophilia A patient about to undergo a tooth extraction. His Factor VIII activity level comes back at 8%. Which agent is appropriate, and why would your answer change if his level were 1%?
A mother is a confirmed carrier of hemophilia B. She has three sons. What is the probability that each son is affected? What would you expect to see on their coagulation panels, and which coagulation test would be normal — helping you exclude a vitamin K deficiency or liver disease as the cause?

Related topics

Coagulation Cascade and PT/PTT Interpretation Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →